- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04842318
Rituximab Maintenance Treatment of Newly Diagnosed Follicular Lymphoma After BR or RCHOP or R2: a Multicenter Clinical Study
April 10, 2021 updated by: Zhao Weili, Ruijin Hospital
Rituximab Maintenance Treatment of Newly Diagnosed Follicular Lymphoma After Induction Therapy of Rituximab Combined With Bendamustine (BR) or Cyclophosphamide, Vincristine, Doxorubicin, Prednisone (RCHOP) or Lenalidomide (R2): a Multicenter Clinical Study
This multi-center clinical study will evaluate the efficacy of Rituximab maintenance treatment of newly diagnosed follicular lymphoma after induction therapy of BR, RCHOP or R2.
Study Overview
Status
Recruiting
Conditions
Detailed Description
Follicular lymphoma (FL) is a lymphoma of B cells in follicular center.
It is a common pathological subtype of lymphoma, and its incidence rate is only next to diffuse large B cell lymphoma (DLBCL).
The initial remission rate is high, but the tumor generally recurrent, making it difficult to be completely cured.
This study attempts to explore the efficacy and safety of rituximab monotherapy maintenance after BR, RCHOP, R2 regimen induction therapy in the treatment of follicular patients, and to find the best way to maximize survival benefit and reduce treatment toxicity for FL patients.
The study can improve the quality of life, prolong the survival and avoid the transformation to invasive lymphoma in patients with follicular lymphoma.
Study Type
Interventional
Enrollment (Anticipated)
789
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: weili Zhao, PhD, MD
- Phone Number: +862164370045
- Email: zwl_trial@163.com
Study Contact Backup
- Name: Pengpeng Xu, PhD, MD
- Phone Number: +862164370045
- Email: pengpeng_xu@126.com
Study Locations
-
-
-
Shanghai, China
- Recruiting
- Ruijin Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Pathologically confirmed CD20 positive follicular lymphoma grade 1, 2, or 3A based on 2016 WHO classification
- Treatment naive
- Age ≥ 18 years
- Indications for treatment confirmed
- Must has measurable lesion in CT or PET-CT prior to treatment
- Considered suitable for RCHOP, BR or R2 regimens
- Informed consented
Exclusion Criteria:
- Transformed follicular lymphoma or 3B follicular lymphoma;
- HBsAg positive and / or HBcAb positive with HBV DNA titer; HCV antibody positive with HCV-RNA; or HIV positive
- Central nervous system or meninges involved
- Any drug contraindication in the treatment plan
- Patients judged by other researchers to be unsuitable for inclusion in the study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: BR+R
Induction Therapy: Rituximab Combined With Bendamustine Maintenance Treatment: Rituximab
|
The patients will be given Bendamustine (90mg/m2 d1,2, every 28 days for total 6 courses) combined with Rituximab (375mg/m2 d0, every 28 days for total 6 courses) followed by Rituximab (375mg/m2 d1, every 3 months for total 8 courses)
|
Experimental: RCHOP+R
Induction Therapy: Rituximab Combined With Cyclophosphamide, Vincristine, Doxorubicin, Prednisone Maintenance Treatment: Rituximab
|
The patients will be given RCHOP (Rituximab 375mg/m2 ivgtt, D0, Cyclophosphamide 750mg/m2, ivgtt D1, doxorubicin 50mg/m2,ivgtt D1, Vincristine 1.4mg/m2(max 2mg), ivgtt D1 Prednisone 60mg/m2 (max 100mg),PO,D1-D5 every 21 days for total 6 courses) followed by Rituximab (375mg/m2 d1, every 3 months for total 8 courses)
|
Experimental: R2+R2
Induction Therapy: Lenalidomide Combined With Rituximab Maintenance Treatment: Lenalidomide Combined With Rituximab
|
The patients will be given Lenalidomide (25mg/d, po, D1-10, every 21 days for total 6 courses) combined with Rituximab (375mg/m2 d0, every 21 days for total 6 courses) followed by Lenalidomide (25mg/d, po, D1-10, every 28 days for total 6 courses) combined with Rituximab (375mg/m2 d1, every 3 months for total 8 courses)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
MRD negative rate of bone marrow at 24 weeks
Time Frame: At 24 weeks
|
Percentage of participants with negative MRD estimated by q-RT-PCR of bone marrow
|
At 24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0
Time Frame: Up to 30 days after completion of study treatment
|
An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment.
An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product.
Preexisting conditions which worsen during a study are also considered as adverse events
|
Up to 30 days after completion of study treatment
|
Overall survival
Time Frame: Baseline up to data cut-off (up to approximately 4 years)
|
Overall survival was defined as the time from the date of diagnosis to the date of death from any cause.
Reported is the percentage of participants with event. of disease progression or relapse, using 2014 Lugano criteria,or death from any cause, whichever occurred first.
|
Baseline up to data cut-off (up to approximately 4 years)
|
Overall response rate
Time Frame: 21 days after 6 cycles of induction therapy (each cycle is 21 days)
|
Percentage of participants with overall response was determined on the basis of investigator assessments according to 2014 Lugano criteria
|
21 days after 6 cycles of induction therapy (each cycle is 21 days)
|
Progression of disease within 24 months
Time Frame: Baseline up to data cut-off (24 months)
|
Progression of disease within 24 months was defined as the rate of disease progression or relapse, using 2014 Lugano criteria, or death from any cause, whichever occurred first.
|
Baseline up to data cut-off (24 months)
|
Event-free survival
Time Frame: Baseline up to data cut-off (up to approximately 4 years)
|
Event-free survival was defined as the time from the date of diagnosis until the date of the first documented day of events.
|
Baseline up to data cut-off (up to approximately 4 years)
|
Time to Progression
Time Frame: Baseline up to data cut-off (up to approximately 4 years)
|
Time to Progression was defined as the time from the date of diagnosis until the date of the first documented day of disease progression, using 2014 Lugano criteria, whichever occurred first.
|
Baseline up to data cut-off (up to approximately 4 years)
|
Duration of response
Time Frame: Baseline up to data cut-off (up to approximately 4 years)
|
Duration of response was defined as the time from the date of diagnosis until the date of the first documented day of disease relapse, using 2014 Lugano criteria, or death from any cause, whichever occurred first.
|
Baseline up to data cut-off (up to approximately 4 years)
|
Time to Next Anti-lymphoma Treatment
Time Frame: Baseline up to data cut-off (up to approximately 4 years)
|
Time to Next Anti-lymphoma Treatment was defined as the time from the date of first treatment until the date patients need to receive next anti-lymphoma treatment on the basis of investigator assessments according to 2014 Lugano criteria
|
Baseline up to data cut-off (up to approximately 4 years)
|
Progression Free Survival
Time Frame: Baseline up to data cut-off (up to approximately 4 years)
|
Progression-free survival was defined as the time from the date of diagnosis until the date of the first documented day of disease progression or relapse, using 2014 Lugano criteria, or death from any cause, whichever occurred first.
|
Baseline up to data cut-off (up to approximately 4 years)
|
MRD negative rate of peripheral blood at 24 weeks
Time Frame: At 24 weeks
|
Percentage of participants with negative MRD estimated by q-RT-PCR of peripheral blood
|
At 24 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 1, 2021
Primary Completion (Anticipated)
March 1, 2023
Study Completion (Anticipated)
March 1, 2024
Study Registration Dates
First Submitted
April 4, 2021
First Submitted That Met QC Criteria
April 10, 2021
First Posted (Actual)
April 13, 2021
Study Record Updates
Last Update Posted (Actual)
April 13, 2021
Last Update Submitted That Met QC Criteria
April 10, 2021
Last Verified
April 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- FL-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Follicular Lymphoma
-
Joseph TuscanoNational Cancer Institute (NCI); Genentech, Inc.; Pharmacyclics LLC.RecruitingAnn Arbor Stage II Follicular Lymphoma | Ann Arbor Stage III Follicular Lymphoma | Ann Arbor Stage IV Follicular Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular LymphomaUnited States
-
National Cancer Institute (NCI)RecruitingRecurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular LymphomaUnited States
-
National Cancer Institute (NCI)TerminatedStage III Grade 1 Follicular Lymphoma | Stage III Grade 2 Follicular Lymphoma | Stage III Grade 3 Follicular Lymphoma | Stage IV Grade 1 Follicular Lymphoma | Stage IV Grade 2 Follicular Lymphoma | Stage IV Grade 3 Follicular LymphomaUnited States
-
Memorial Sloan Kettering Cancer CenterFox Chase Cancer Center; Pharmacyclics LLC.TerminatedFollicular Lymphoma | Follicular Lymphoma, Grade 1 | Follicular Lymphoma, Grade 2 | Follicular Lymphoma Grade IIIaUnited States
-
Olivia Newton-John Cancer Research InstituteBristol-Myers Squibb; Barwon Health; Austin Health; Eastern Health; Fiona Stanley... and other collaboratorsRecruitingFollicular Lymphoma Stage II | Follicular Lymphoma Stage III | Follicular Lymphoma Stage IVAustralia
-
Robert LowskyNational Cancer Institute (NCI); Janssen, LP; The Leukemia and Lymphoma Society; Rising Tide FoundationCompletedMantle Cell Lymphoma | Marginal Zone Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular LymphomaUnited States
-
Massachusetts General HospitalTG TherapeuticsActive, not recruitingLymphoma | Follicular Lymphoma | Marginal Zone Lymphoma | Follicular Lymphoma, Grade 1 | Follicular Lymphoma Grade IIIa | Marginal Zone B Cell Lymphoma | Follicular Lymphoma Grade 2United States
-
Fondazione Italiana Linfomi ONLUSCompletedFollicular Lymphoma, Grade 1 | Follicular Lymphoma, Grade 2 | Follicular Lymphoma Grade 3AItaly
-
National Cancer Institute (NCI)Celgene CorporationActive, not recruitingAnn Arbor Stage III Grade 1 Follicular Lymphoma | Ann Arbor Stage III Grade 2 Follicular Lymphoma | Ann Arbor Stage IV Grade 1 Follicular Lymphoma | Ann Arbor Stage IV Grade 2 Follicular Lymphoma | Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma | Ann Arbor Stage II Grade 3 Non-Contiguous... and other conditionsUnited States
-
Epizyme, Inc.RecruitingFollicular Lymphoma | Relapsed/Refractory Follicular Lymphoma | Refractory Follicular LymphomaUnited States, China, Spain, France, Taiwan, United Kingdom, Australia, Korea, Republic of, Canada, Italy, Hungary, Poland, Belgium, Germany
Clinical Trials on BR for 6 cycles +R for 8 cycles
-
Japan Clinical Oncology GroupMinistry of Health, Labour and Welfare, JapanCompletedBreast Cancer | Neoplasm MetastasisJapan
-
Cancer Institute and Hospital, Chinese Academy...Hoffmann-La RocheUnknownCarcinoma, Invasive Ductal, BreastChina
-
Laurent Pharmaceuticals Inc.Recruiting
-
Icahn School of Medicine at Mount SinaiLEO PharmaCompletedActinic KeratosisUnited States
-
Galway ClinicUnknownMetabolic Syndrome | Prostate Cancer | Intermittent FastingIreland
-
Hellenic Oncology Research GroupTerminated
-
Shandong Provincial HospitalUnknownHepatosplenic T-cell Lymphoma | Peripheral T-Cell Lymphoma, Not Otherwise Specified | ALK-negative Anaplastic Large Cell Lymphoma | Angioimmunoblastic T Cell Lymphoma | Enteropathy Associated T Cell Lymphoma | Subcutaneous Panniculitis Like T Cell LymphomaChina
-
First People's Hospital of FoshanUnknown
-
Radiation Therapy Oncology GroupNational Cancer Institute (NCI); NRG Oncology; Eastern Cooperative Oncology Group and other collaboratorsCompletedBrain and Central Nervous System TumorsUnited States
-
Novartis PharmaceuticalsRecruitingFollicular Lymphoma (FL)Australia, Korea, Republic of, Spain, Singapore, Poland, Taiwan, Hungary, Romania, Slovakia